Former CEO of Proteus reflects on the dramatic fall of 'digital pill' unicorn -

"The US healthcare system’s focus on activity rather than value for money was behind the demise of Proteus Digital Health and its “digital pill”, which measured whether schizophrenia patients took their meds, according to the company’s former CEO.
At the Frontiers Health conference Andrew Thompson spoke to pharmaphorum’s web editor Catherine Longworth about lessons that can be learned from the company’s troubled attempt to market the technology.
Together with Japan’s Otsuka Pharmaceuticals, the company produced the ground-breaking smart pill Abilify Mycite (aripiprazole).
But the partnership ran into trouble after poor uptake by payers in the US and an ill-fated fundraiser.
After disappointing sales, Proteus filed for bankruptcy earlier this year and in September, Otsuka ended up buying what was left of Proteus for $20 million.
Although Novartis was reportedly also interested in the company’s technology, it was a huge fall from grace for Proteus Digital Health which was once valued at $1.5 billion..." Lire la suite